402 related articles for article (PubMed ID: 33960745)
21. Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.
Metro G; Lunardi G; Bennati C; Chiarini P; Sperduti I; Ricciuti B; Marcomigni L; Costa C; Crinò L; Floridi P; Gori S; Chiari R
J Neurooncol; 2016 Sep; 129(2):355-61. PubMed ID: 27324494
[TBL] [Abstract][Full Text] [Related]
22. Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
Burudpakdee C; Wong W; Seetasith A; Corvino FA; Yeh W; Gubens M
Lung Cancer; 2018 May; 119():103-111. PubMed ID: 29656744
[TBL] [Abstract][Full Text] [Related]
23. Alectinib for advanced
Ly AC; Olin JL; Smith MB
Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
[TBL] [Abstract][Full Text] [Related]
24. Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study.
Ito K; Yamanaka T; Hayashi H; Hattori Y; Nishino K; Kobayashi H; Oya Y; Yokoyama T; Seto T; Azuma K; Fukui T; Kozuki T; Nakamura A; Tanaka K; Hirano K; Yokoi T; Daga H; Sakata S; Fujimoto D; Mori M; Maeno K; Aoki T; Tamura A; Miura S; Watanabe S; Akamatsu H; Hataji O; Suzuki K; Hontsu S; Azuma K; Bessho A; Kubo A; Okuno M; Nakagawa K; Yamamoto N
Eur J Cancer; 2021 Mar; 145():183-193. PubMed ID: 33486442
[TBL] [Abstract][Full Text] [Related]
25. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
26. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
Morcos PN; Nueesch E; Jaminion F; Guerini E; Hsu JC; Bordogna W; Balas B; Mercier F
Cancer Chemother Pharmacol; 2018 Jul; 82(1):129-138. PubMed ID: 29748847
[TBL] [Abstract][Full Text] [Related]
27. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract][Full Text] [Related]
28. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
Gainor JF; Sherman CA; Willoughby K; Logan J; Kennedy E; Brastianos PK; Chi AS; Shaw AT
J Thorac Oncol; 2015 Feb; 10(2):232-6. PubMed ID: 25526238
[TBL] [Abstract][Full Text] [Related]
29. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
30. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
Wolf J; Helland Å; Oh IJ; Migliorino MR; Dziadziuszko R; Wrona A; de Castro J; Mazieres J; Griesinger F; Chlistalla M; Cardona A; Ruf T; Trunzer K; Smoljanovic V; Novello S
ESMO Open; 2022 Feb; 7(1):100333. PubMed ID: 35042152
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.
Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J
Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627
[TBL] [Abstract][Full Text] [Related]
32. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
33. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
Ou SH; Weitz M; Jalas JR; Kelly DF; Wong V; Azada MC; Quines O; Klempner SJ
Lung Cancer; 2016 Jun; 96():15-8. PubMed ID: 27133743
[TBL] [Abstract][Full Text] [Related]
34. Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.
Harada D; Isozaki H; Kozuki T; Yokoyama T; Yoshioka H; Bessho A; Hosokawa S; Takata I; Takigawa N; Hotta K; Kiura K;
Thorac Cancer; 2021 Mar; 12(5):643-649. PubMed ID: 33470536
[TBL] [Abstract][Full Text] [Related]
35. Alectinib Superior to Crizotinib for ALK+ NSCLC.
Cancer Discov; 2017 Aug; 7(8):OF5. PubMed ID: 28600466
[TBL] [Abstract][Full Text] [Related]
36. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases.
Lin JJ; Jiang GY; Joshipura N; Ackil J; Digumarthy SR; Rincon SP; Yeap BY; Gainor JF; Shaw AT
J Thorac Oncol; 2019 Apr; 14(4):683-690. PubMed ID: 30529198
[TBL] [Abstract][Full Text] [Related]
38. Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.
Hochmair M; Weinlinger C; Schwab S; Naber J; Setinek U; Krenbek D; Urban MH; Fabikan H; Watzka S; Koger R; Fazekas A; Bitterlich E; Valipour A; Burghuber OC
Anticancer Drugs; 2019 Aug; 30(7):e0787. PubMed ID: 31305295
[TBL] [Abstract][Full Text] [Related]
39. Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study.
Zou Z; Xing P; Hao X; Wang Y; Song X; Shan L; Zhang C; Liu Z; Ma K; Dong G; Li J
BMC Med; 2022 Jan; 20(1):12. PubMed ID: 35039026
[TBL] [Abstract][Full Text] [Related]
40. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]